46
Novo Nordisk announces a significant price reduction for its weight-loss medication, Wegovy, lowering the monthly cost to $499 for all doses. This initiative is part of the company's new direct-to-consumer platform, NovoCare Pharmacy, which aims to enhance accessibility for uninsured or underinsured patients by offering home delivery services.
The price adjustment positions Wegovy more competitively within the rapidly expanding obesity treatment market, currently valued at $47.4 billion and projected to reach $471.1 billion by 2032. Novo Nordisk and Eli Lilly are anticipated to be. . .
